Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

EMTRICITABINE; TENOFOVIR ALAFENAMIDE

EMTRICITABINE;TENOFOVIR ALAFENAMIDE

Standard Dose
200MG/25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview EMTRICITABINE; TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 216875 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient EMTRICITABINE;TENOFOVIR ALAFENAMIDE Form and strength TABLET;ORAL - 200MG/25MG Sponsor AUROBINDO PHARMA Submission history Latest submission status date: 2022-12-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview EMTRICITABINE; TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 216875 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient EMTRICITABINE;TENOFOVIR ALAFENAMIDE Form and strength TABLET;ORAL - 200MG/25MG Sponsor AUROBINDO PHARMA Submission history Latest submission status date: 2022-12-19 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
EMTRICITABINE; TENOFOVIR ALAFENAMIDE (EMTRICITABINE;TENOFOVIR ALAFENAMIDE) | Drug Monograph | MedicHelpline